Author contributions
JJ
RECRUITMENT
ND and OG developed the cellular methodology and performed the immunogenicity analyses. KS prepared the statistical plan and performed the statistical analysis with YH. CB chaired the trial management committee, oversaw patient recruitment and treated patients. EB and BM developed the methodology and manufactured the cellular vaccine to GMP standards. GMW, PRD and MAB developed the synthetic methodology and manufactured GMP grade peptides. GC, JJ, STSC and GFP developed the synthetic methodology and manufactured GMP grade α-GalCer, and conducted analytical and stability studies on the peptides and α-GalCer. CEW, TO, JL, AM, MD and RW provided local clinical support. CB, KS, VAH, JM, MMcC, CEW, MD, and MPF undertook clinical project development and management, analysis and reporting. ND, OG, KS, YH, BM, AA-H, OKB and IFH analysed the immunological data. ND, OG, KS, CB and IFH wrote the manuscript, with input from the other authors. CB, KS, MPF, GFP, RK, PRD and IFH conceived and designed the study.